Recs

0

WebMD Looks Weak

WebMD (Nasdaq: HLTH  ) still looks a little sick to me. When we checked in with the company last fall, it had just lowered guidance, downgrading expectations to $0.10 per share for the fourth quarter (before special charges). The actual number came in at $0.09 per stub -- before charges. The number after stripping out those charges was $0.03 per share, which is still better than the big red penny from the year-earlier period.

For the full year, revenues climbed 10.6% to $964 million. The net loss of $0.05 per share shows an improvement over 2002's red ink of $0.16 per share. So why am I looking so grave and asking WebMD to turn its head and cough? The symptoms include government investigations, cash provided by financing and, what I perceive through my stethoscope to be, a lack of focus.

The Feds have asked WebMD to open up and say, "ahhh." Both the Justice Department and the SEC are investigating WebMD's books, suspecting there may be funny business related to one of the firm's predecessor companies. But this may be the least of its worries.

WebMD's health care services systems provide the bulk of sales these days, but they battle in a competitive field populated with firms such as McKesson (NYSE: MCK  ) , NDCHealth (NYSE: NDC  ) , Per-Se Technologies (Nasdaq: PSTI  ) , Cerner (Nasdaq: CERN  ) , and Quality Systems (Nasdaq: QSII  ) .

And despite some good gains in revenue, WebMD has an appetite for more cash than it can generate. Yesterday, the firm announced a private placement of $100 million in convertible shares sold to CalPERS. The latest balance sheets show our patient continuing to cough up large quantities of common stock and convertible debt.

Also worrisome is the company's acquisition-based growth strategy. The CalPERS announcement hinted strongly that the incoming funds might be used for more shopping. This would come on top of nearly three dozen purchases in recent years. I drew some flack lately when I criticizedChinadotcom's (Nasdaq: CHINA  ) similar growth strategy, but I'm sticking to my guns.

No, acquisitions don't always mean deworsification, as Peter Lynch dubbed it. But when companies going through big upheavals are constantly looking outside for revenue generators, you ought to ponder whether your investment dollars might not better off out there, too, perhaps in one of those prospective acquisition targets.

Fool contributor Seth Jayson has no stake in any company mentioned above. View his Fool profile here.


Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

DocumentId: 534418, ~/Articles/ArticleHandler.aspx, 2/13/2012 2:10:03 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 2 days ago Sponsored by:
DOW 12,801.23 -89.23 -0.69%
S&P 500 1,342.64 -9.31 -0.69%
NASD 2,903.88 -23.35 -0.80%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

2/10/2012 4:01 PM
MCK $81.34 Down -0.85 -1.03%
McKesson CAPS Rating: ****
PSTI $2.56 Down -0.07 -2.65%
PLURISTEM THERAPEU… CAPS Rating: **
QSII $43.09 Down -0.65 -1.49%
Quality Systems CAPS Rating: ****
CERN $69.27 Down -0.12 -0.17%
Cerner Corp CAPS Rating: **
CHINA $0.00 Down +0.00 +0.00%
CDC Software CAPS Rating: ****
HLTH.DL $0.00 Down +0.00 +0.00%
HLTH Corp CAPS Rating: ***

Advertisement